Related Experiment Video
Updated: Jun 2, 2026
06:12
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
HER-2/neu in bladder carcinoma
S Tommasi1, P Ditonno, M Sisto
1POLICLIN BARI,DEPT UROL,BARI,ITALY. UNIV BARI,INST PATHOL,BARI,ITALY.
International Journal of Oncology
|May 6, 2011
Summary
This study found no significant link between HER-2/neu gene alterations and bladder cancer outcomes like recurrence or survival. HER-2/neu status did not predict patient prognosis in the studied cohort.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The HER-2/neu gene is implicated in various cancers.
- Understanding its role in bladder cancer is crucial for prognosis.
Purpose of the Study:
- To investigate the relationship between HER-2/neu gene alterations (amplification and overexpression) and clinicopathological features in bladder cancer.
- To determine if HER-2/neu status can identify a subgroup of patients with poor prognosis regarding recurrence, progression, and survival.
Main Methods:
- Analysis of HER-2/neu DNA amplification and protein overexpression in 66 bladder cancer patients using Southern and Western blot techniques.
- Statistical evaluation of findings in relation to pathological staging, tumor grading, tumor multiplicity, and clinical outcomes.
Main Results:
- HER-2/neu amplification was observed in 13% and overexpression in 39% of cases.
- No significant association was found between HER-2/neu alterations and pathological staging or tumor grading.
- Multifocal tumors showed a higher prevalence of HER-2/neu amplification and overexpression compared to monofocal tumors.
- Statistical analyses revealed no significant correlation between HER-2/neu amplification/overexpression and clinical outcomes such as time to recurrence, time to progression, or survival.
Conclusions:
- HER-2/neu gene alterations are not significantly associated with pathological characteristics in bladder cancer.
- HER-2/neu status does not appear to be a reliable predictor of tumor relapse, progression, or patient survival in bladder cancer.
